• Embla Medical published the transcript of its Q2 2026 results call attended by CEO Sveinn Solvason, CFO Arna Sveinsdéttir, and sell-side analysts.
• Q2 sales were $259 million; 11% reported growth, 6% organic growth; EBITDA margin was 22%, helped by Prosthetics & Neuro Orthotics strength.
• Patient Care sales fell 2%; management flagged shortfalls in Sweden tenders and France integration, while the Americas improved for a third straight quarter.
• Full-year organic sales growth guidance narrowed to 5%-7% from 5%-8%; EBITDA margin guidance kept at 20%-22%.
• Net U.S. tariff refunds totaled $3 million in H1; management expects up to $1 million more in H2, with timing uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Embla Medical hf. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.